

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary) (PTO-1449)	PATENT DOCKET NO.		SERIAL NO.
	20011/1371		09/704,306 #14
	APPLICANT		
	Beck et al.		
FILING DATE		GROUP ART UNIT	
November 2, 2000		1624	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
BC	1	3,666,763	05/30/1972	Grethe et al.	260	289 R	
BC	2	3,947,456	03/30/1976	Rheiner	260	289 R	
BC	3	4,843,071	06/27/1989	Hohenwarter	514	217	
BC	4	4,902,710	02/20/1990	Foster et al.	514	438	
BC	5	5,444,070	08/22/1995	Moldt et al.	514	304	
BC	6	5,532,244	07/02/1996	Wong et al.	514	255	
BC	7	5,654,296	08/05/1997	Kato et al.	514	213	
BC	8	5,789,449	08/04/1998	Norden	514	651	
BC	9	6,121,261	09/19/2000	Glatt et al.	514	236.2	
BC	10	6,136,803	10/24/2000	Freedman et al.	514	231.2	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
BC	11	EP 0 400 319 A1	04/20/1990	Europe	—	—	
BC	12	EP 0 599 338 A2	06/01/1994	Europe	—	—	

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

BC	13	Maryanoff et al., "Pyrroloisoquinoline Antidepressants. 2. In-Depth Exploration of Structure-Activity Relationships," <u>J. Med. Chem.</u> 30(8):1433-1454 (1987)
BC	14	Kihara et al., "Synthesis and Pharmacological Evaluation of Phenolic 2-Methyl-4-Phenyl-1,2,3,4-Tetrahydroisoquinolin-4-ols As New Norepinephrine Potentiators," <u>Drug Design and Discovery</u> 11(3):175-183 (1994)
BC	15	Kihara et al., "Synthesis and Enantioselectivity of Optically Active 1- and 3-Substituted 4-Phenyl-1,2,3,4-Tetrahydroisoquinolin-4-ols and Related Compounds As Norepinephrine Potentiators," <u>Chemical and Pharmaceutical Bulletin</u> 43(9):1543-1546 (1995)
BC	16	Cliffe, "(S)-N-tert Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide[S]-WAY-100135): A Selective Antagonist at Presynaptic and Postsynaptic-SHT Receptors" <u>J. Med. Chem.</u> 36:1509-10 (1988)
EXAMINER		DATE CONSIDERED
Brenda Coleman		Oct. 15, 2003
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary)  (PTO-1449 )	ATT. DOCKET NO. 20011/1371	SERIAL NO. 09/704,306	#18
	APPLICANT Beck et al.		
	FILING DATE November 2, 2000	GROUP ART UNIT 1624	



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

RECEIVED

MAR 31 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

BC		1	Aihara et al., "Increasing 5-Lipoxygenase Inhibitory Activities by Oxidative Conversion of o-Methoxyphenols to Catechols Using a Cu <sup>2+</sup> - Ascorbic Acid - O <sub>2</sub> System," <u>Chem. Pharm. Bull.</u> , 38(3):842-844 (1990)
EXAMINER		Brenda Coleman	
DATE CONSIDERED		Oct. 15, 2003	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			